📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. (2023)

First Author: Khoo SH

Attributed to: G2P-UK; A National Virology Consortium to address phenotypic consequences of SARSCoV-2 genomic variation funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(22)00644-2

PubMed Identifier: 36272432

Publication URI: http://europepmc.org/abstract/MED/36272432

Type: Journal Article/Review

Volume: 23

Parent Publication: The Lancet. Infectious diseases

Issue: 2

ISSN: 1473-3099